N
Nicholas Bandarenko
Researcher at Duke University
Publications - 55
Citations - 2453
Nicholas Bandarenko is an academic researcher from Duke University. The author has contributed to research in topics: Thrombotic thrombocytopenic purpura & Ticlopidine. The author has an hindex of 25, co-authored 55 publications receiving 2347 citations. Previous affiliations of Nicholas Bandarenko include University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.
Zbigniew M. Szczepiorkowski,Jeffrey L. Winters,Nicholas Bandarenko,Haewon C. Kim,Michael L. Linenberger,Marisa B. Marques,Ravindra Sarode,Joseph E. Schwartz,Robert Weinstein,Beth H. Shaz +9 more
TL;DR: The Fourth ASFA Special Issue is significantly modified in comparison to the previous editions and a new concept of a fact sheet has been introduced that succinctly summarizes the evidence for the use of therapeutic apheresis.
Journal ArticleDOI
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
Nancy M. Archin,Joseph J. Eron,Sarah Palmer,Anne Hartmann-Duff,Jeffery A Martinson,Ann Wiegand,Nicholas Bandarenko,John L. Schmitz,Ronald J. Bosch,Alan L. Landay,John M. Coffin,David M. Margolis +11 more
TL;DR: The prospective addition of valproic acid to stable antiretroviral therapy reduced the frequency of resting CD4+ T-cell infection in a minority of volunteers.
Journal ArticleDOI
United States thrombotic thrombocytopenic purpura apheresis study group (US TTP ASG): Multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange
TL;DR: This study strived to assess the current practice of TPE in TTP in order to provide direction for prospective controlled clinical trials and minimize patient exposure to blood products and procedures, shorten the clinical course of TTP, and reduce mortality.
Journal ArticleDOI
Clopidogrel-associated TTP: an update of pharmacovigilance efforts conducted by independent researchers, pharmaceutical suppliers, and the Food and Drug Administration.
Anaadriana Zakarija,Nicholas Bandarenko,Dilip K. Pandey,Amy R. Auerbach,Dennis W. Raisch,Benjamin Kim,Hau C. Kwaan,June M. McKoy,Brian P. Schmitt,Charles J. Davidson,Paul R. Yarnold,Philip B. Gorelick,Charles L. Bennett,Charles L. Bennett +13 more
TL;DR: Completeness, timeliness, and certainty of diagnosis were best for cases obtained by active surveillance, intermediate for cases reported to the pharmaceutical supplier, and poorest forcases reported directly to the FDA.
Journal ArticleDOI
Overexpression of p53 and HER-2/neu Proteins as Prognostic Markers in Early Stage Breast Cancer
Jeffrey R. Marks,Peter A. Humphrey,Katherine Wu,Donald A. Berry,Nicholas Bandarenko,Billie-Jo M. Kerns,J. D. Iglehart +6 more
TL;DR: The p53 and HER-2/neu oncogenes have proven but limited prognostic value and an approach that combines several molecular genetic markers with established pathologic criteria may help physicians to make more accurate predictions of prognosis in patients with early stage breast cancer.